Stocktoria
bioAffinity Technologies, Inc. BIAF
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research · website · IPO 2022-08-26
bioAffinity Technologies, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | — | 0.1% | — |
| Operating margin | -171.6% | -95.6% | -100.9% | -58.1% | — |
| Net margin | -242.0% | -96.6% | -100.5% | -118.2% | — |
| FCF margin | -152.4% | -78.4% | -76.7% | -62.2% | — |
| Return on assets | -136.0% | -138.8% | -96.5% | -66.9% | -435.3% |
| Return on equity | -204.9% | -347.4% | -163.5% | -73.8% | 40.1% |
| Current ratio | 2.60 | 0.87 | 1.77 | 10.50 | 0.11 |
| Revenue growth | -34.2% | 18.5% | 14.5% | — | — |
Source: SEC EDGAR filings · CIK 0001712762 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.